Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial

How Semiphysiological Population Pharmacokinetic Modeling Incorporating Active Hepatic Uptake Supports Phase II Dose Selection of RO7049389, A Novel Anti–Hepatitis B Virus Drug

(2021) Valérie Cosson et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

JNJ-56136379, an HBV Capsid Assembly Modulator, is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients with Chronic Infection

(2020) Fabien Zoulim et al.   GASTROENTEROLOGY

A Five-in-One First-in-Human Study To Assess Safety, Tolerability, and Pharmacokinetics of RO7049389, an Inhibitor of Hepatitis B Virus Capsid Assembly, after Single and Multiple Ascending Doses in Healthy Participants

(2020) Sheng Feng et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

PS-156-Antigen suppression effect of the core protein allosteric modulator R07049389 in AAV-HBV mice is accompanied by transient upregulation of immune-cell gene signatures in the liver

(2019) Xue Zhou et al.   JOURNAL OF HEPATOLOGY

BAY 41-4109-mediated aggregation of assembled and misassembled HBV capsids in cells revealed by electron microscopy

(2019) Virgile Rat et al.   ANTIVIRAL RESEARCH

Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial

(2019) Man-Fung Yuen et al.   Lancet Gastroenterology & Hepatology

Novel non-heteroarylpyrimidine (HAP) capsid assembly modifiers have a different mode of action from HAPs in vitro

(2018) Angelica Corcuera et al.   ANTIVIRAL RESEARCH

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

(2018) Norah A. Terrault et al.   HEPATOLOGY

In vitro and in vivo antiviral characterization of RO7049389, a novel small molecule capsid assembly modulator for the treatment of chronic hepatitis B

(2018) X. Zhou et al.   JOURNAL OF HEPATOLOGY

Hepatitis B virus infection

(2018) Man-Fung Yuen et al.   Nature Reviews Disease Primers

Hepatitis B core protein as a therapeutic target

(2017) Lung-Yi Mak et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Hepatitis B cure: From discovery to regulatory approval

(2017) Anna S. Lok et al.   HEPATOLOGY

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

(2017) Pietro Lampertico et al.   JOURNAL OF HEPATOLOGY

Core protein: A pleiotropic keystone in the HBV lifecycle

(2015) Adam Zlotnick et al.   ANTIVIRAL RESEARCH

Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection

(2015) Kosh Agarwal et al.   JOURNAL OF HEPATOLOGY

High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core protein

(2015) Klaus Klumpp et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hepatitis B flares in chronic hepatitis B: Pathogenesis, natural course, and management

(2014) Ming-Ling Chang et al.   JOURNAL OF HEPATOLOGY